TiGenix : agreement signed for commercialization of ChondroCelect in the Middle East
(Thomson Reuters ONE) -
Regulated information
november 13, 2012
TiGenix signs agreement for commercialization of ChondroCelect in the Middle
East
Leuven (Belgium) - November 13, 2012 - TiGenix NV (Euronext Brussels: TIG) and
pharmaceutical marketing and distribution company Genpharm in Dubai, United Arab
Emirates, today announced that they have signed an exclusive agreement for the
commercialization of ChondroCelect(®) in the Middle East region.
TiGenix and Genpharm have entered into an exclusive distribution agreement to
facilitate the successful commercialization of ChondroCelect in Saudi Arabia,
UAE, Kuwait, Bahrain, Qatar, Oman (GCC), Lebanon, Jordan, Syria, Iraq, Iran and
Egypt.
Under the terms of the agreement, Genpharm will facilitate patients' access to
ChondroCelect in the Middle East countries by obtaining the required regulatory
approvals, and providing training and product support to surgeons and healthcare
professionals in selected orthopedic centers. TiGenix continues to be the
marketing authorisation holder and will be responsible for logistics and the
manufacturing of ChondroCelect.
"We are pleased to have Genpharm as our partner to help us enter into the
emerging healthcare market in the Middle East," said Eduardo Bravo, CEO of
TiGenix. "The Middle East countries are generally affluent, offer state-of-the-
art medical care and are very receptive to advanced therapeutics. We very much
look forward to work with the Genpharm team and support them in the roll-out of
ChondroCelect."
"We are delighted to work with TiGenix to bring ChondroCelect to patients and
orthopedic surgeons across the Middle East region. We have the opportunity to
offer an innovative and effective therapeutic solution that will improve the
quality of life of many patients suffering from knee cartilage deterioration,"
said Karim Smaira, CEO of Genpharm.
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company
with a marketed product for cartilage repair, ChondroCelect®, and a strong
pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the
Netherlands).
For more information please visit www.tigenix.com.
About Genpharm Services
Genpharm Services is a pharmaceutical marketing company, based in the Dubai
Biotechnology and Research Park, UAE. Through evidence based medicine, Genpharm
provides healthcare organizations with innovative therapeutic solutions in niche
and rare genetic disease areas, market access strategies and sustainable
commercial solutions in the Middle East and North Africa Region.
For more information, please visit www.genpharmservices.com.
For more information
TiGenix NV
Eduardo Bravo
Chief Executive Officer
eduardo.bravo(at)tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta(at)tigenix.com
Hans Herklots
hans.herklots(at)tigenix.com
+32 16 39 60 97
Genpharm Services
Karim Smaira
Chief Executive Officer
karim.smaira(at)genpharmservices.com
+971 4 422 70 10
Ashwathy Anil
Business Development
ashwathy(at)genpharmservices.com
+971 4 422 70 10
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognized
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1657057]
Unternehmensinformation / Kurzprofil:
Datum: 13.11.2012 - 07:01 Uhr
Sprache: Deutsch
News-ID 202447
Anzahl Zeichen: 6479
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : agreement signed for commercialization of ChondroCelect in the Middle East"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
